Recurrent Small Cell Lung Cancer (SCLC) Recruiting Phase 2 Trials for Metformin (DB00331)
Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent
Indication | Status | Phase |
---|---|---|
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC)) | Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT03994744 | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | Treatment |